{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T15:02:15Z","timestamp":1767193335275,"version":"3.48.0"},"reference-count":23,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"unspecified","delay-in-days":28,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Development Center for Medical Science & Technology National Health"},{"name":"Zhejiang Biozon Medical Technology Co., Ltd"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,8,7]]},"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Secondary hypertension accounts for 5%\u201310% of all hypertensive patients. Among these conditions, endocrine hypertension, such as primary aldosteronism (PA), Cushing\u2019s syndrome (CS) and pheochromocytoma and paraganglioma (PPGL), is a common and significantly harmful cause. With advancements in diagnostic techniques, the prevalence of endocrine hypertension is much higher than previously reported, but large-scale epidemiological survey data in this field are still lacking in China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This is a multicentre prospective cohort study to investigate the epidemiological characteristics of endocrine hypertension, such as PA, PPGL and CS, in the Chinese hypertensive population. Standardised clinical assessments, biochemical tests and mass spectrometry-based screening will be performed to identify endocrine hypertension caused by PA, PPGL and CS. The primary outcome is the prevalence and characteristics of endocrine hypertension. Secondary outcomes include establishing standardised detection methods. Participants will be followed for at least 1 year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The protocol was approved by the Medical Ethics Committee of Beijing Children\u2019s Hospital ((2023)-E-028-Y), the coordinating site and all participating centres. Results will be published in a peer-reviewed journal and presented at scientific meetings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>ChiCTR2300075747.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Protocol version<\/jats:title>\n                    <jats:p>Version 7 (23 June 2022).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-098446","type":"journal-article","created":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T19:15:12Z","timestamp":1756667712000},"page":"e098446","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Screening for endocrine hypertension in China: protocol for a multicentre prospective cohort study"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8262-2236","authenticated-orcid":false,"given":"Zhanyang","family":"Zhou","sequence":"first","affiliation":[{"name":"Heart Failure Center, Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Yin","sequence":"additional","affiliation":[{"name":"Heart Failure Center, Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3986-1804","authenticated-orcid":false,"given":"Huanhuan","family":"Miao","sequence":"additional","affiliation":[{"name":"Heart Failure Center, Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shijie","family":"Yang","sequence":"additional","affiliation":[{"name":"Beijing Anzhen Hospital Affiliated to Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Heart Failure Center, Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,8,31]]},"reference":[{"key":"2025123106481179000_15.8.e098446.1","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1001\/jamainternmed.2016.0190","article-title":"The Burden of Hypertension and Associated Risk for Cardiovascular Mortality in China","volume":"176","author":"Lewington","year":"2016","journal-title":"JAMA Intern Med"},{"key":"2025123106481179000_15.8.e098446.2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.018912"},{"key":"2025123106481179000_15.8.e098446.3","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht534"},{"key":"2025123106481179000_15.8.e098446.4","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-4061"},{"key":"2025123106481179000_15.8.e098446.5","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1210\/clinem\/dgab348","article-title":"Performance of the Aldosterone to Renin Ratio as a Screening Test for Primary Aldosteronism","volume":"106","author":"Hung","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2025123106481179000_15.8.e098446.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8529(02)00013-0"},{"key":"2025123106481179000_15.8.e098446.7","doi-asserted-by":"publisher","DOI":"10.1291\/hypres.27.193"},{"key":"2025123106481179000_15.8.e098446.8","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.tcm.2021.03.005","article-title":"Primary aldosteronism","volume":"32","author":"Funder","year":"2022","journal-title":"Trends Cardiovasc Med"},{"key":"2025123106481179000_15.8.e098446.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.01.052"},{"key":"2025123106481179000_15.8.e098446.10","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1097\/CM9.0000000000002927","article-title":"Summary of the 2022 Report on Cardiovascular Health and Diseases in China","volume":"136","author":"Wang","year":"2023","journal-title":"Chin Med J"},{"key":"2025123106481179000_15.8.e098446.11","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","article-title":"Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis","volume":"6","author":"Monticone","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025123106481179000_15.8.e098446.12","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9082435","article-title":"Cardiovascular Manifestations and Complications of Pheochromocytomas and Paragangliomas","volume":"9","author":"Y-Hassan","year":"2020","journal-title":"J Clin Med"},{"key":"2025123106481179000_15.8.e098446.13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.11.1427"},{"key":"2025123106481179000_15.8.e098446.14","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.0954-6820.1986.tb02755.x","article-title":"Pheochromocytoma in Sweden 1958-1981. An analysis of the National Cancer Registry Data","volume":"220","author":"Stenstr\u00f6m","year":"1958","journal-title":"Acta Med Scand"},{"key":"2025123106481179000_15.8.e098446.15","first-page":"802","article-title":"Occurrence of pheochromocytoma in Rochester","volume":"58","author":"Beard","year":"1950","journal-title":"Mayo Clin Proc"},{"key":"2025123106481179000_15.8.e098446.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61375-1"},{"key":"2025123106481179000_15.8.e098446.17","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00235-7"},{"key":"2025123106481179000_15.8.e098446.18","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2021.105924","article-title":"Intratumoral steroid profiling of adrenal cortisol-producing adenomas by liquid chromatography- mass spectrometry","volume":"212","author":"Teuber","year":"2021","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2025123106481179000_15.8.e098446.19","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000002510"},{"key":"2025123106481179000_15.8.e098446.20","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2003.024703"},{"key":"2025123106481179000_15.8.e098446.21","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.032380"},{"key":"2025123106481179000_15.8.e098446.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.07.059"},{"key":"2025123106481179000_15.8.e098446.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.02.052"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-098446","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T14:50:52Z","timestamp":1767192652000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-098446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":23,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8,31]]},"published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1136\/bmjopen-2024-098446"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-098446","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2025,8]]}}}